Abstract: The global avapritinib tablets market is projected to reach USD 1.81 billion by 2030, expanding at a CAGR of 28.0% during the forecast period, according to QYResearch. Avapritinib—a KIT/PDGFRA kinase inhibitor approved for advanced gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM)—is manufactured by only two companies worldwide: Blueprint Medicines, the original developer, and CStone Pharmaceuticals, its China partner. This duopoly structure is among the most concentrated in the pharmaceutical industry. The market’s growth trajectory is driven by label expansion in systemic mastocytosis, China’s national reimbursement inclusion, and domestic manufacturing localization. This analysis examines the competitive structure, the clinical differentiation underpinning avapritinib’s orphan drug pricing, CStone’s China commercialization pathway, Sanofi’s USD 9.1 billion acquisition of Blueprint and its integration implications, and the strategic considerations shaping market evolution through 2030.

1. Product Profile and Clinical Differentiation
   Avapritinib is a precision oncology therapeutic targeting mutations in KIT and PDGFRA, two receptor tyrosine kinases whose aberrant activation drives distinct subsets of GIST and systemic mastocytosis. Its clinical significance lies in addressing patient populations that have limited or no effective treatment alternatives. In GIST, avapritinib is approved for PDGFRA exon 18 mutation-driven tumors, including the D842V mutation that confers resistance to imatinib and other conventional tyrosine kinase inhibitors. In systemic mastocytosis, avapritinib treats both indolent and advanced forms, addressing a disease where mast cell accumulation causes debilitating symptoms and, in advanced cases, organ damage.

The drug’s mechanism—blocking the abnormal protein signaling that drives cancer cell proliferation—places it within the kinase inhibitor class, but its selectivity and potency against specific PDGFRA and KIT mutations distinguish it from broader-spectrum TKIs. This precision positioning supports orphan drug pricing and specialized cancer center adoption, as GII Research notes that avapritinib’s market significance stems from substantial clinical benefits in challenging cases, leading to premium pricing typical of orphan drugs .

The global market’s growth rate—28.0% CAGR per QYResearch—reflects both label expansion and geographic commercialization. However, this figure warrants contextualization against alternative estimates. GII Research values the global avapritinib market at USD 787.2 million in 2024, growing to USD 1.40 billion by 2033 at 6.6% CAGR . The divergence between 28.0% and 6.6% is substantial and likely reflects different base years, scope definitions, or assumptions about generic entry and pricing pressure. The higher figure may capture a narrower period of rapid adoption from a small base, while the lower figure embeds assumptions about market maturity and competitive dynamics over a longer horizon.

2. The Two-Manufacturer Duopoly
   The most striking structural feature of the avapritinib market is its two-manufacturer composition. Blueprint Medicines, the Cambridge, Massachusetts-based biotechnology company that discovered and developed the drug, holds the original patents and manufactures for the U.S. and European markets under the trade names Ayvakit and Ayvakyt. CStone Pharmaceuticals, the Shanghai-based biopharmaceutical company, holds the China rights and manufactures for the Chinese market under the trade name 泰吉华 (Taijihua).

This duopoly is not the result of market competition but of contractual and regulatory architecture. Blueprint licensed China rights to CStone, creating a geographic division of responsibilities that mirrors the companies’ respective market access capabilities. CStone’s 2024 approval for localization production and its February 2025 commencement of domestic supply represent the operational realization of this arrangement . The localization approval allows CStone to manufacture avapritinib tablets (300 mg and 100 mg) within China rather than importing finished product, a shift that CStone states will drive gross margin expansion by eliminating import costs and currency exposure.

The duopoly structure creates a predictable competitive environment within each geography but also introduces dependency risks. For patients and payers in markets outside the U.S., Europe, and China, access depends on Blueprint’s global commercial infrastructure or CStone’s export capability, neither of which has prioritized broad geographic expansion. The absence of generic competition reflects both patent protection and the technical complexity of manufacturing a targeted kinase inhibitor with the impurity profile and bioavailability characteristics required for regulatory approval.

3. China Commercialization and the NRDL Pathway
   CStone’s China commercialization strategy illustrates the pathway for innovative oncology drugs in the world’s second-largest pharmaceutical market. Avapritinib received initial National Reimbursement Drug List (NRDL) inclusion in December 2023, a critical milestone that determines patient affordability and hospital formulary access. The NRDL renewal in December 2025 secured continued reimbursement through the next negotiation cycle .

The NRDL inclusion transforms the commercial calculus. Without reimbursement, avapritinib’s orphan drug pricing would limit access to a small fraction of eligible patients. With NRDL coverage, the cost to patients falls to levels comparable with other reimbursed oncology therapies, expanding the treated population. CStone’s 2025 revenue from pharmaceutical product sales—RMB 78.3 million across avapritinib, pralsetinib, and sugemalimab—provides a combined figure that does not isolate avapritinib’s contribution, but the NRDL renewal and domestic supply launch signal that avapritinib is a meaningful component of the company’s commercial portfolio .

The domestic supply transition carries strategic implications beyond cost. Local manufacturing reduces lead times, improves supply chain resilience, and demonstrates CStone’s commitment to the Chinese market—factors that may influence NRDL negotiations and hospital adoption decisions. For Blueprint (now Sanofi), the arrangement generates royalty or profit-sharing revenue without requiring direct investment in Chinese manufacturing infrastructure, a capital-efficient model for accessing a market with distinct regulatory and pricing dynamics.

4. Sanofi’s Acquisition of Blueprint Medicines
   The most consequential structural development for the avapritinib market is Sanofi’s acquisition of Blueprint Medicines, completed in 2025 for approximately USD 9.1 billion . The transaction transferred ownership of Ayvakit/Ayvakyt and Blueprint’s broader pipeline of KIT inhibitor therapies to the French pharmaceutical major, fundamentally altering the competitive landscape from an independent biotech to a division of a global diversified company.

The integration has proceeded with the workforce and facility consolidation typical of large pharmaceutical acquisitions. Sanofi disclosed in August 2026 that it will lay off 229 employees from Blueprint’s Massachusetts operations between October 2026 and June 2027, representing roughly one-third of Blueprint’s pre-acquisition workforce of 682 . Two legacy Blueprint facilities in Cambridge, including the former global headquarters at 45 Sidney Street, will close, with remaining employees relocating to Sanofi’s Cambridge Crossing campus. The layoffs coincide with the departure of several senior Blueprint executives, including former CEO Kate Haviland, former CSO Percy Carter, and former CCO Philina Lee .

For avapritinib’s market trajectory, the Sanofi integration introduces both opportunities and uncertainties. On the opportunity side, Sanofi’s global commercial infrastructure, payer relationships, and regulatory expertise could accelerate avapritinib’s penetration in markets where Blueprint’s standalone resources were limited. Sanofi’s stated strategic rationale—enhancing its pipeline and accelerating its transformation into a leading immunology company—suggests that avapritinib’s role within the portfolio may be as a rare disease asset with stable revenue rather than a high-growth priority . On the uncertainty side, post-acquisition restructurings can disrupt commercial momentum, and the departure of executives who built the avapritinib franchise may affect institutional knowledge and customer relationships.

5. Market Drivers and Access Constraints
   The avapritinib market’s growth is supported by several structural drivers. The expanding recognition of avapritinib within regulatory frameworks for additional clinical indications increases the eligible patient population, as GII Research notes, fostering clinician confidence and prompting investment in distribution and awareness initiatives . The growing emphasis on comprehensive molecular diagnostics—routine PDGFRA and KIT sequencing—enables more effective patient identification, as previously unrecognized mutations are detected and treatment shifts toward targeted therapies . Companion diagnostic integration is a parallel trend, enhancing patient identification precision and streamlining clinical decision-making.

The primary restraint is cost and reimbursement complexity. GII Research identifies high treatment costs and complicated pricing models as significant challenges that hinder patient access and limit reimbursement support . Payers often impose restrictions or prior authorization processes that diminish prescribing flexibility, even when clinical advantages are evident. Budgetary constraints affect hospital formularies, compelling providers to consider alternatives or postpone avapritinib adoption. These economic factors dampen demand and require stakeholder collaboration to address affordability and accessibility before the market can achieve its growth potential.

The contrast between the QYResearch 28.0% CAGR and the GII 6.6% CAGR may partially reflect differing assumptions about how quickly these access constraints are resolved. The higher growth rate implies rapid adoption as reimbursement expands and diagnostic pathways mature; the lower rate embeds persistent friction from payer restrictions and cost barriers.

6. Strategic Considerations and Market Outlook
   The avapritinib market presents a profile of high growth from a specialized base, extreme supply concentration, and a transition in corporate ownership that may reshape commercial priorities. Three strategic considerations emerge for stakeholders.

Sanofi’s integration execution will determine whether avapritinib’s commercial momentum is sustained. The layoffs and facility consolidations are standard cost-rationalization measures, but they carry risk of disrupting the specialized commercial and medical affairs capabilities that orphan drug commercialization requires. Sanofi’s track record with acquired rare disease assets and its commitment to the KIT inhibitor pipeline—including BLU-808, for which Blueprint shareholders received contingent value rights —will shape whether avapritinib receives the investment needed to expand its label and geographic reach.

China’s NRDL and localization trajectory represent the most significant incremental volume opportunity. CStone’s domestic supply capability and NRDL renewal position avapritinib for volume growth in a market where reimbursement determines access. The gross margin expansion from localization, combined with the expanded patient population from reimbursement, creates a favorable economic profile for CStone. The strategic question is whether China volumes can offset potential pricing pressure in developed markets, where payer scrutiny of orphan drug costs is intensifying.

Diagnostic infrastructure development is a prerequisite for market expansion. Avapritinib’s efficacy depends on identifying patients with specific PDGFRA or KIT mutations, and the availability of routine molecular testing varies widely across geographies. Markets with established companion diagnostic pathways—the U.S., Western Europe, and increasingly China—will capture the majority of avapritinib utilization, while markets without such infrastructure will see slower adoption regardless of reimbursement status. Investment in diagnostic capacity is thus a parallel requirement to commercial expansion.

The competitive hierarchy is unlikely to change before 2030, given the patent protection and manufacturing complexity that sustain the two-manufacturer structure. Growth will depend on label expansion, geographic reimbursement, and Sanofi’s ability to integrate Blueprint’s commercial capabilities without eroding the specialized focus that orphan drug commercialization demands. The divergence in growth forecasts underscores the uncertainty inherent in projecting a market where access constraints and corporate strategy intersect.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp